Fantastic, isn’t it! Information technologies are evolving at such a pace that it seems there is something new to be excited about almost every week. This week’s headlines: MIT has announced artificial intelligence software that can see people through walls, virtual reality is being used for health and safety training, and a study claiming a chatbot has better diagnosis accuracy that human physician.
In our sector, just as with the chatbot diagnosis system, it is clear these new technologies also create new risks and new challenges. Like self-driving cars, which are forcing us to reconsider fundamental questions of accountability and safety decision making – we need to understand the risks and adapt our strategies for using and controlling these technologies around those risks.
GAMP5® is ten years old - older than many of the technologies that are finding their way into the regulated life sciences sector, and definitely older than our understanding of many of the risks we now have to deal with.
So – is it still relevant?
My answer is a resounding Yes! GAMP5® was written to be a flexible and adaptable framework for ensuring compliance of all types of computerized system, with risk management at its heart.
This year, the 2018 ISPE Annual Meeting & Expo track on Information Systems will focus on new technologies and new risks. We will build on the themes of previous years and explore the opportunities new technologies are offering and how the principles of GAMP guidance can be applied.
Our theme for the Information Systems track is “Realizing Transformational Technologies in Our Regulated World” and we are very excited to have sessions covering the following topics:
I look forward to meeting you in Philadelphia this November at the 2018 ISPE Annual Meeting & Expo – come and join us as we explore what the future holds.
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...